Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,699 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
Nakagawa T, Matsushima T, Kawano S, Nakazawa Y, Kato Y, Adachi Y, Abe T, Semba T, Yokoi A, Matsui J, Tsuruoka A, Funahashi Y. Nakagawa T, et al. Among authors: kato y. Cancer Sci. 2014 Jun;105(6):723-30. doi: 10.1111/cas.12409. Epub 2014 Apr 28. Cancer Sci. 2014. PMID: 24689876 Free PMC article.
E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Yamada K, Hori Y, Inoue S, Yamamoto Y, Iso K, Kamiyama H, Yamaguchi A, Kimura T, Uesugi M, Ito J, Matsuki M, Nakamoto K, Harada H, Yoneda N, Takemura A, Kushida I, Wakayama N, Kubara K, Kato Y, Semba T, Yokoi A, Matsukura M, Odagami T, Iwata M, Tsuruoka A, Uenaka T, Matsui J, Matsushima T, Nomoto K, Kouji H, Owa T, Funahashi Y, Ozawa Y. Yamada K, et al. Among authors: kato y. Cancer Res. 2021 Feb 15;81(4):1052-1062. doi: 10.1158/0008-5472.CAN-20-0782. Epub 2021 Jan 6. Cancer Res. 2021. PMID: 33408116
Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.
Adachi Y, Kamiyama H, Ichikawa K, Fukushima S, Ozawa Y, Yamaguchi S, Goda S, Kimura T, Kodama K, Matsuki M, Miyano SW, Yokoi A, Kato Y, Funahashi Y. Adachi Y, et al. Among authors: kato y. Cancer Res. 2022 Jan 15;82(2):292-306. doi: 10.1158/0008-5472.CAN-20-2426. Epub 2021 Nov 9. Cancer Res. 2022. PMID: 34753772 Free PMC article.
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y, Matsuki M, Matsuoka Y, Ghosh S, Kitano H, Nomoto K, Matsui J, Funahashi Y. Kato Y, et al. PLoS One. 2019 Feb 27;14(2):e0212513. doi: 10.1371/journal.pone.0212513. eCollection 2019. PLoS One. 2019. PMID: 30811474 Free PMC article.
Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium.
Eng JW, Kato Y, Adachi Y, Swaminathan B, Naiche LA, Vadakath R, Sakamoto Y, Nakazawa Y, Tachino S, Ito K, Abe T, Minoshima Y, Hoshino-Negishi K, Ogasawara H, Kawakatsu T, Nishimura M, Katayama M, Shimizu M, Tahara K, Sato T, Suzuki K, Agarwala K, Iwata M, Nomoto K, Ozawa Y, Imai T, Funahashi Y, Matsui J, Kitajewski J. Eng JW, et al. Among authors: kato y. Cancer Res Commun. 2024 Jul 1;4(7):1881-1893. doi: 10.1158/2767-9764.CRC-24-0081. Cancer Res Commun. 2024. PMID: 38984877 Free PMC article.
8,699 results